Genmab A+s

Biontech Se

Ivan Kuzmanov

Ugur Sahin

Janine Schuurman

Aran Frank Labrijn

Friederike Gieseke

Joost J Neijssen

Alexander Muik

Esther Cornelia Wilhelmina Breij

Sina Fellermeier-kopf

Lars Guelen

Bart-Jan De Kreuk

Richard Hibbert

Karsten Beckmann

Claudia Paulmann

Patricia Garrido Castro

Jordan Blum

The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.

Monoclonal antibodies directed against programmed death-1 protein and their use in medicine

Growing community of inventors

Mainz, Germany

Ivan Kuzmanov